BioLineRx Ltd. to Present Data from the Successfully Completed Phase IIb Trial of BL-1020 at European Conference on Schizophrenia Research
JERUSALEM--(BUSINESS WIRE)--BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.